Laurie Smaldone Alsup

Laurie has over 30 years of biopharmaceutical industry experience, specializing in commercially successful product approvals and global regulatory strategy. She currently serves as the Chief Medical Officer and Chief Scientific Officer of NDA Group AB, a regulatory and drug product development consulting company. Prior to joining NDA Group AB, Laurie served as the President and Chief Scientific Officer of PharmApprove LLC, a regulatory communications consultancy. Previously, Laurie served as the President and Chief Executive Officer of Phytomedics, Inc., a clinical stage company with a focus on auto-immune, inflammatory, and metabolic diseases. She began her career at Bristol Myers Squibb and spent 20 years in roles of increasing responsibility in clinical development, regulatory strategy, and corporate risk management. She currently serves on the boards of directors of Blackberry, Ltd., Arvinas, Inc., Theravance Biopharma, Inc., and Kinnate Biopharma, Inc.

Laurie holds a B.A. in Biological Sciences from Fordham College and a M.D. from Yale School of Medicine and is a medical oncologist by training.